Idea principal
In 33 observational studies, time in range rose by 3.75% (95% CI 2.56 to 4.92) during lockdown in people with type 1 diabetes, while type 2 diabetes showed a short-term, non-significant drift upward in HbA1c (+0.14; 95% CI -0.13 to 0.40). Type 2 evidence came from only 8 studies, and HbA1c in type 1 did not change significantly.
Study design
Revisión de evidencia
Reading basis
Published abstract
Reading focus
Design & applicability
Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.
Pregunta de investigación
Lockdowns during the COVID-19 pandemic disrupted routine care and daily life, and it was unclear whether blood sugar control got better or worse. The authors reviewed how lockdown affected glycaemic control in people with type 1 and type 2 diabetes.
Población y método
Systematic review of observational studies found in the Cochrane Library, MEDLINE via PubMed, Web of Science Core Collection, EMBASE and CINAHL until April 2021: 33 studies, 25 on type 1 and 8 on type 2 diabetes, covering 2881 type 1 and 1823 type 2 patients. Meta-analysis was done for HbA1c and time in range (TIR).
Resultados
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1In type 1 diabetes, 18 of 25 studies (72%) reported significant improvements in glycaemic outcomes. Pooled TIR rose by 3.75% (95% CI 2.56 to 4.92).
- 2Pooled HbA1c in type 1 changed by -0.05% (95% CI -0.31 to 0.21), a difference that is not statistically distinguishable from zero.
- 3In type 2 diabetes, 4 of 8 studies (50%) observed worse glycaemic control, and pooled HbA1c rose by 0.14 (95% CI -0.13 to 0.40), which is not significant.
- 4Body weight deteriorated in 3 of the studies that reported it (75%), though not significantly.
Límites e incertidumbre
- 1Observational before-and-after comparisons have no control group, so the lockdown effect cannot be separated from other changes over time.
- 2Only 8 studies covered type 2 diabetes, and the confidence interval for its HbA1c change includes no change.
- 3Whether glycaemic changes reflect real behaviour change or differences in how often data were collected is not clear from the abstract.
- 4This reading is based on the abstract only.
Relevancia práctica
For people with type 1 diabetes, lockdown was associated with more time in range, possibly linked to better self-care and digital tools, but not with a clear HbA1c change. In type 2 diabetes the evidence points to a possible short-term slip that is not conclusive. Adjustments to diabetes care should be made with your clinician.
Tus datos
If you use a continuous glucose monitor, time in range is exactly the measure this review tracked: compare weeks using the same sensor and settings, and look at trends rather than single days. Changes in routine such as less movement or irregular meals are worth noting beside the data.
Cómo interpretar la evidencia
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Resumen estructurado de los autores English
El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.
Background
In 2019, a new virus known as severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has emerged. Coronavirus disease 2019 (COVID-19) was classified as a pandemic in a short period of time. In order to reduce the spread of COVID-19, many countries have imposed a lockdown with movement restrictions, social distancing and home confinement, which has affected routine healthcare activities and everyday life. The aim of this systematic review was to examine the impact of the COVID-19 lockdown on glycemic control in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D).
Methods
We systematically identified studies by searching the databases Cochrane Library, MEDLINE via PubMed, Web of Science Core Collection, EMBASE, and CINAHL until April 2021. We included n = 33 observational studies of which n = 25 investigated T1D and n = 8 T2D.
Results
Overall, we analyzed n = 2881 T1D patients and n = 1823 T2D patients. Glycemic values in patients with T1D improved significantly during lockdown. Overall, n = 18 (72%) T1D studies indicated significant improvements in glycemic outcomes. Meta-analysis revealed a mean difference in HbA1c of - 0.05% (95% CI - 0.31 to 0.21) due to lockdown, and in time in range (TIR) of + 3.75% (95% CI 2.56 to 4.92). Lockdown determined a short-term worsening in glycemic values in patients with T2D. Overall, n = 4 (50%) publications observed deteriorations in glycemic control. Meta-analysis demonstrated a mean difference in HbA1c of + 0.14 (95% CI - 0.13 to 0.40) through the lockdown. Moreover, n = 3 (75%) studies reported a not significant deterioration in body weight.
Conclusions
Glycemic values in people with T1D significantly improved during COVID-19 lockdown, which may be associated with positive changes in self-care and digital diabetes management. In contrast, lockdown rather determined a short-term worsening in glycemic parameters in patients with T2D. Further research is required, particularly into the causes and effective T2D management during lockdown.
Fuentes y atribución
Impact of COVID-19 lockdown on glycemic control in patients with type 1 and type 2 diabetes mellitus: a systematic review.
Eberle C, Stichling S.
Diabetology & metabolic syndrome · 2021-09-07
DOI: 10.1186/s13098-021-00705-9 ↗PubMed · 34493317 ↗Europe PMC · Licencia registrada: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada
Fuentes verificadas 2026-11-01
Guías prácticas
Leer en contexto
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

